SCHEMBL4144463

SCHEMBL4144463

N#Cc1ccc(N(Cc2noc(-c3cccc(C(F)(F)F)c3)n2)CC(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.45
NR1H3 Q13133 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
AR P10275 6/20 0.40
CTSS P25774 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
PGR P06401 2/20 0.38
POLB P06746 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160058 0.93 L3MBTL1 (0.41) NR1H2NR1H3L3MBTL1MAPTMAPK1
SCHEMBL4145083 0.91 AR (0.47) L3MBTL1MAPTNPC1RAB9AAR
SCHEMBL4139876 0.90 AR (0.40) NR1H2NR1H3ARPGR
SCHEMBL4137799 0.88 GRM5 (0.43) NR1H2NR1H3L3MBTL1ARCTSS
SCHEMBL4153574 0.86 AR (0.40) ARPGR
SCHEMBL4147167 0.84 S1PR1 (0.44) NR1H2NR1H3MAPTNPC1RAB9A
SCHEMBL4137720 0.83 NR1H2 (0.46) NR1H2NR1H3L3MBTL1MAPTNPC1
SCHEMBL4137903 0.83 AR (0.40) L3MBTL1ARPGRKDM4EALDH1A1
SCHEMBL4153700 0.83 AR (0.38) ARPGR
SCHEMBL4136947 0.83 AR (0.43) ARNPSR1PGRPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US claimed
EP-1888512-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-20 EP claimed
WO-2006133216-A2 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO claimed
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US disclosed
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US disclosed
EP-1888512-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-20 EP disclosed
WO-2006133216-A2 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170907-A1 Chemical Compounds NR3C2, NR5A1, NR3C1 NR1H2 61/4885NR1H3 57/4885L3MBTL1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.